BTIG lowered the firm’s price target on Outset Medical (OM) to $3 from $4 and keeps a Buy rating on the shares. The firm is updating its model after the company’s positive pre-announcement of Q4 revenue along with a $169M private placement financing earlier this month, noting that its price target cut reflects equity dilution, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical Strengthens Financial Position with Key Moves
- Disney to own 70% of Fubo, Trudeau to resign as party leader: Morning Buzz
- Outset Medical Secures New Financing and Debt Facility
- Outset Medical reports Q4 revenue $29M, consensus $27.85M
- Outset Medical announces $169M private placement financing